Change of Adviser and Broker

RNS Number : 4071G
Oxford Biomedica PLC
06 June 2013







Oxford BioMedica plc Change of Adviser and Broker


Oxford, UK - 6 June 2013: Oxford BioMedica ("the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that it has appointed Nomura Code Securities Limited as its sponsor, financial adviser and broker with immediate effect.




For further information, please contact:



Oxford BioMedica plc:

Lara Mott, Head of Corporate Communications


Tel: +44 (0)1865 783 000


Nomura Code Securities

Juliet Thompson

Jonathan Senior

Christopher Golden



Tel: +44 (0)20 7776 1200

Media Enquiries:

Mary-Jane Elliott/Sarah Macleod/Claire Dickinson M:Communications

Tel: +44 (0)20 7920 2360



Notes to editors


1. Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at and

This information is provided by RNS
The company news service from the London Stock Exchange